Olmesartan treatment in spontaneously hypertensive rats increased ACE2 mRNA in the thoracic aorta fivefold compared with vehicle (P<0.05), whereas atenolol and hydralazine had no effect.
Does AT1 receptor blockade with olmesartan increase ACE2 and angiotensin-(1-7) expression and improve vascular remodeling in spontaneously hypertensive rats compared to other antihypertensives or vehicle?
AT1 receptor blockade with olmesartan increases ACE2 and angiotensin-(1-7) expression and improves vascular remodeling in the thoracic aorta of spontaneously hypertensive rats, independent of blood pressure lowering.
Effect estimate: fivefold greater
p-value: p=<0.05
When increased in vascular tissues, angiotensin-converting enzyme 2 (ACE2), a carboxypeptidase that hydrolyzes angiotensin II to angiotensin-(1-7), may augment the growth inhibitory and vasodilatory effects of the heptapeptide. We investigated the regulation of ACE2 and angiotensin-(1-7) expression in aortas and carotid arteries of 12-wk-old male spontaneously hypertensive rats (SHR) by determining the effect of sustained angiotensin type 1 (AT(1)) receptor blockade with olmesartan (10 mg.kg(-1).day(-1), n = 13) compared with those that received atenolol (30 mg.kg(-1).day(-1), n = 13), hydralazine (10 mg.kg(-1).day(-1), n = 13), or vehicle (n = 21). Systolic blood pressures were approximately 30% lower (P < 0.05) in rats treated for 2 wk with olmesartan compared with vehicle-treated rats. Both atenolol and hydralazine produced similar decreases in systolic blood pressure. ACE2 mRNA in the thoracic aorta of olmesartan-treated rats (n = 8) was fivefold greater (P < 0.05) than that in vehicle-treated rats (n = 16), whereas atenolol (n = 8) or hydralazine (n = 8) had no effect. Immunostaining intensities in rats treated with olmesartan (n = 5) were also associated with increased (P < 0.05) ACE2 and angiotensin-(1-7) in thoracic aorta media compared with vehicle-treated rats. In contrast, immunostaining intensities for both ACE2 and angiotensin-(1-7) were not different from vehicle (n = 5) in carotid arteries of SHR medicated with either atenolol (n = 5) or hydralazine (n = 5). A comparison of vessel wall dimensions showed that olmesartan selectively reduced the thoracic aorta media-to-lumen ratio (P < 0.05) and media thickness (P < 0.05) without an effect on carotid artery morphometry. Compared with vehicle-treated SHR, vascular hypertrophy determined from media and lumen measurements was not changed in SHR given either atenolol or hydralazine. These data represent the first report of ACE2 and angiotensin-(1-7) expression in the aorta and carotid arteries of SHR. Increased ACE2 and angiotensin-(1-7) in association with altered dimensions of the thoracic aorta but not carotid arteries in response to olmesartan treatment provides evidence that this pathway is regulated by AT(1) receptors and may be important in mediating the pressure-independent vascular remodeling effects of angiotensin peptides.
Igase et al. (Sat,) conducted a other in Hypertension (n=60). Olmesartan vs. Atenolol, hydralazine, or vehicle was evaluated on ACE2 mRNA in the thoracic aorta (fivefold greater, p=<0.05). Olmesartan treatment in spontaneously hypertensive rats increased ACE2 mRNA in the thoracic aorta fivefold compared with vehicle (P<0.05), whereas atenolol and hydralazine had no effect.